Baader Investment Conference

6008

FRESENIUS MEDICAL CARE

Munich | September 21, 2016






Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on its views with respect to future events an financial performance. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA independent of being the reported or the adjusted number. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in US-\$ if not mentioned otherwise.











AGENDA



Business update: Q2 2016

Financials & outlook



Ci-Ce




1

2

3

Expected global dialysis patient growth

- ▶ Expected patient growth of around 6% p.a.
- Driven by age, lifestyle and higher life expectancy








Dialysis services worldwide: Patients treated¹ **North America EMEA** 186,096 FMC FMC 58,528 DaVita Diaverum 24,200 185,200 U.S. Renal Care 24,000 KfH 18,700 **Asia-Pacific** Latin America 29,917 FMC FMC 27,007 Baxter 8,270 **B.Braun** 5,300 4.730 Diaverum Showai-Kai 5,150 USD We lead in every major market, ~73bn treating > 290,000 patients worldwide Market ¹ as of June 30, 2015, based on company statements and own estimates.



YEARS

-Market position by major product groups 2015

	Position 1
Dialyzers	FMC
Dialysis machines	FMC
Hemodialysis concentrates	FMC
Bloodlines	FMC
Peritoneal dialysis products	Baxter



Global presence: products & services US China **Europe** Japan Inukai, Buzen Concord, Ogden Germany, France, Italy Changshu **EMEA** North America 659 clinics 2,210 clinics Asia-Pacific 320 clinics Latin America 229 clinics Mexico Guadalajara, Reynosa Bad Homburg **Company Headquarters Fresenius Medical Care has** HongKong Regional Headquarters Asia-Pac. 37 production sites worldwide **Regional Headquarters America** Waltham





YEAR

AGENDA

Market dynamics

Business update: Q2 2016

Financials & outlook





1

2


3

Q2: Accelerated earnings growth

Q2 2016 Highlights


- Solid revenue growth driven by very good results in health care services
- North America again with excellent operating performance
- Care Coordination continues to show significant top-line growth
- New innovative hemodialysis therapy system 6008 launched in May
- For the first time providing services to more than 300,000 patients worldwide
- On track to achieve full year guidance

Q2 2016 Performance (US\$ million)





Q2: Solid revenue development in all segments







Q2: Quality outcomes remain stable

	North	America	E	MEA	Latin Ar	merica ¹	Asia-P	acific ¹
% of patients	Q2 2016	Q1 2016	Q2 2016	Q1 2016	Q2 2016	Q1 2016	Q2 2016	Q1 2016
Kt/V ≥ 1.2	98	98	96	96	92	92	97	97
No catheter (>90 days)	84	85	81	82	82	82	91	91
Hemoglobin = 10 – 12 g/dl	73	72	77	78	52	52	58	58
Hemoglobin = 10 - 13 g/dl (International)	78	77	77	77	69	68	66	66
Albumin ≥ 3.5 g/dl	81	82	90	91	90	90	87	89
Phosphate \leq 5.5 mg/dl	63	64	76	78	77	75	71	70
Calcium 8.4 – 10.2 mg/dl	83	84	73	74	74	76	75	74
Hospitalization days, per patient	10.0	10.0	9.4	9.4	3.6	3.5	4.0	4.3

¹ Outcome data in these regions might be more volatile over time as clinic data will be added.






Q2: Health care services revenue continues to grow Same

	Q2 2016 US\$ million	Q2 2015 US\$ million	Growth in %	Growth in %cc	Organic growth in %	market growth in %
Total health care	3,571	3,345	7	8	7	3
North America	2,938	2,722	8	8	7	3
of which Care Coordination	564	468	21	21	17	n.a.
EMEA	331	309	7	9	3	3
Asia-Pacific	177	164	8	2	4	5
Latin-America	125	139 ¹	$(10)^1$	18*	19	2

- 4% increase in dialysis treatments
- Positive impact from a higher volume with commercial payers
- Care Coordination with significant organic growth



¹ Pro-forma health care services revenue, reflecting sale of Fresenius Medical Care's clinics in Venezuela in July 2015 (\$11 million revenue in Q2 2015).



9%

5%

4%

Q2: Dialysis products grow despite strong Q2 2015

	Q2 2016 US\$ million	Q2 2015 US\$ million	Growth in %	Growth in %cc
Total dialysis products	849	854	(1)	2
North America	230	224	2	2
EMEA	345	359	(4)	(3)
Asia-Pacific	220	212	4	9
Latin America	50	53	(5)	8
Corporate	4	6	(30)	(31)

- Increased sales of dialyzers and machines
- Very tough comparison due to exceptionally strong performance in the comparable quarter last year
- Foreign currency headwinds outside of North America







AGENDA







Q2/H1: Strong profit increase


	Q2 2016 US\$ million	Q2 2015 US\$ million	Growth in %	H1 2016 US\$ million	H1 2015 US\$ million	Growth in %
Net revenue	4,420	4,199	5	8,626	8,159	6
Operating income (EBIT)	641	547	17	1,181	1,051	12
EBIT-margin in %	14.5	13.0	150bp	13.7	12.9	80bp
Net interest expense	102	102	1	208	204	2
Income before taxes	539	445	21	973	847	15
Income tax expense	169	135	24	306	273	12
Tax rate in %	31.3	30.4	90bp	31.5	32.2	(70bp)
Non-controlling interest	76	69	11	145	124	17
Net income	294	241	22	522	450	16

Revenue for the first half increased by 8% constant currency, in line with full-year guidance.

 Net income supported by lower cost for healthcare supplies and savings from Global Efficiency Program.











Q2: Cash flow development and credit profile

	Q2 2016 in \$ r	H1 2016 nillion	Q2 2015 in \$ m	H1 2015 illion
Operating cash flow	678	857	385	832
in % of revenue	15.3	9.9	9.2	10.2
Capital expenditures, net	(252)	(498)	(214)	(411)
Free cash flow	426	359	171	421
Free cash flow, after acquisitions and investments	359	202	116	355




A reconciliation to the most directly comparable U.S. GAAP financial measures is provided in the attachments.





YEAR



- Savings from the Global Efficiency Program are included
- Acquisitions 2015/2016 are not included
- Net income growth based on US\$ 1,057 million in 2015

-2020 growth strategy

Opening up new business areas

Growing in our core business

Enhancing products and treatments

Increasing flexibility and efficiency







- We expect an average increase in net income in the high single-digit percentage range for the same period.
- We will continue to grow our dialysis services and products business.
- We plan to further expand our Care Coordination activities.



CREATING A FUTURE WORTH LIVING





Attachment 1

Reconciliation of non-US-GAAP financial measures to the most comparable US-GAAP measure

US\$ million

Debt	FY 2014 1)	FY 2015	Q2 2016
Short term borrowings	133	109	705
+ Short term borrowing from related parties	5	19	3
+ Current portion of long-term debt and capital lease obligations	314	664	675
 + Long-term debt and capital lease obligations less current portion 	9,014	7,854	7,702
TOTAL debt	9,466	8,646	9,085
EBITDA	FY 2014 ²⁾	FY 2015 ²⁾	Q2 2016 ²⁾
			_

Last twelve month operating income (EBIT)	2,347	2,327	2,466
+ Last twelve month depreciation and amortization	716	717	739
+ Non-cash charges	57	83	89
EBITDA (annualized)	3,120	3,127	3,294
Total Debt ¹⁾ / EBITDA	3.0	2.8	2.8

1) Reclassification of debt issuance costs from current / non-current assets to long-term liabilities

2) EBITDA: including largest acquisitions





Attachment 2

Reconciliation of non-US-GAAP financial measures to the most comparable US-GAAP measure

US\$ million

Cash Flow	Q2 2015	Q2 2016	H1 2015	H1 2016
Acquisitions, investments and net purchases of intangible assets	(79)	(213)	(101)	(304)
+ Proceeds from divestitures	24	146	35	147
= Acquisitions and investments, net of divestitures	(55)	(67)	(66)	(157

Capital expenditures, net	Q2 2015	Q2 2016	H1 2015	H1 2016
Purchase of property, plant and equipment	(217)	(256)	(418)	(506)
- Proceeds from sale of property, plant & equipment	3	4	7	8
= Capital expenditure, net	(214)	(252)	(411)	(498)






H1: Health care services & product revenue Same Organic market H1 2016 H1 2015 Growth Growth growth growth US\$ US\$ million million in % in %cc in % in % Total health care services 6,985 6,527 7 9 7 4 7 3 North America 5,770 5,293 9 9 1,086 902 20 20 17 of which Care Coordination _ EMEA 632 610 4 8 3 4 Asia-Pacific 345 328 5 3 4 6 238 296 17 2 Latin-America (20)9 Growth H1 2016 H1 2015 Growth

	US\$ million	US\$ million	in %	in %cc
Total dialysis products	1,641	1,632	1	4
North America	442	424	4	4
EMEA	675	687	(2)	1
Asia-Pacific	426	401	6	12
Latin America	90	105	(14)	2
Corporate	8	15	(48)	(48)



cc = constant currency

YEARS



The DSO increase in the North America Segment in Q1 2016 is mainly due to an adjustment which impacted invoicing. This effect was largely resolved in Q2 2016.





H1: Patients, treatments, clinics

	Patients as of June 30, 2016	Treatments H1 2016, in million	Clinics as of June 30, 2016
North America	186,096	14.2	2,249
Growth in %	4	5	2
EMEA	58,528	4.3	700
Asia-Pacific	27,007	1.9	324
Latin America	29,917	2.3	231
Total	301,548	22.8	3,504
Growth in %	4	4	2





Excha	nge rates	Q2 2015	H1 2015	Q2 2016	H1 2016
€:\$	Period end	1.119	1.119	1.110	1.110
	Average	1.105	1.116	1.129	1.116
\$:CNY	Period end	6.200	6.200	6.643	6.643
	Average	6.204	6.221	6.543	6.539
\$:RUB	Period end	55.729	55.729	64.421	64.421
	Average	52.674	57.932	65.828	70.165
\$:ARS	Period end	9.105	9.105	14.911	14.911
	Average	8.960	8.822	14.211	14.326



YĖĄRS

U.S. dialysis days per quarter							
	Q1	Q2	Q3	Q4	Full year		
2014	76	78	79	80	313		
2015	76	78	79	79	312		
2016	78	78	79	79	314		
2017	77	78	79	78	312		



Constant currency: Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "at constant exchange rates" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. Under U.S. GAAP, revenues received in local (non-U.S. dollar) currency are translated into U.S. dollars at the average exchange rate for the period presented. When we use the term "constant currency," it means that we have translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. We then calculate the change, as a percentage, of the current period revenues using the prior period exchange rates versus the prior period revenues. This resulting percentage is a non-GAAP measure referring to a change as a percentage "at constant exchange rates."

We believe that revenue growth is a key indication of how a company is progressing from period to period and that the non-GAAP financial measure constant currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on its revenue from period to period. However, we also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element of our revenue and could significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency revenue into U.S. dollars. We do not evaluate our results and performance without considering both constant currency period-over-period changes in non-U.S. GAAP revenue on the one hand and changes in revenue prepared in accordance with U.S. GAAP on the other. We caution the readers of this report to follow a similar approach by considering data on constant currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue prepared in accordance with U.S. GAAP. We present the fluctuation derived from U.S. GAAP revenue next to the fluctuation derived from non-GAAP revenue. Because the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.

-Financial calendar *

Oct 27, 2016 Report on 3rd quarter 2016

sion Conference, London
n, Milan
Conference, Scottsdale
e Days Asia, Singapore/Hong Kong
inkfurt

 \ast Please note that dates and/or participation might be subject to change





Contacts

FME Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. Germany

WKN: ISIN:

Ticker: FME or FMS (NYSE) 578 580 DE00057858002

Oliver Maier

Head of Investor Relations and **Corporate Communications** +49-(0) 6172-609-2601 Tel: Email: <u>oliver.maier@fmc-aq.com</u>

Robert Adolph

Director Investor Relations Tel.: +49-(0) 6172-609-2477 Email: robert.adolph@fmc-aq.com

Juliane Beckmann

Senior Manager Investor Relations +49-(0) 6172-609-5216 Tel.: Email: juliane.beckmann@fmc-ag.com

Terry Morris

VP Investor Relations North America Tel: +1 - 800 - 948 - 2538Email: terry.morris@fmc-na.com







Baader Investment Conference

6008

FRESENIUS MEDICAL CARE

Munich | September 21, 2016



